Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721. by Twentyman, P. R.
Br. J. Cancer (1981) 43, 745
MODIFICATION OF TUMOUR AND HOST RESPONSE TO
CYCLOPHOSPHAMIDE BY MISONIDAZOLE AND BY WR 2721
P. R. TWENTYMAN
From the Medical Research Council Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge, England
Received 19 December 1980 Accepted 2 March 1981
Summary.-The effect has been studied of adding either misonidazole (MISO) or the
radioprotective drug, WR2721, to cyclophosphamide (CY) treatment of mice bearing
either the RIF-1 or KHT sarcomas. In RIF-1, the growth delay due to CY was
increased by the addition of 1 mg/g of MISO. At doses below 75 mg/kg of CY, the
effect was dose modifying but, at higher doses, the curves were parallel. When the
MISO dose was reduced to 0.33 mg/g, the effect was reduced but not entirely lost.
Only a small enhancement of CY response in the KHT tumour was seen with single
doses, but the enhancement was greater with fractionated doses. The growth delay
produced by CY in both tumour systems was reduced if WR 2721 (400 mg/kg) was
given 30 min earlier. At a CY dose of75-100 mg/kg the dose-modifying factor (DMF)
was 0-7-0-8 but, at least in the RIF-1 tumour, was not so low at higher doses of CY.
Determination of the LD50 for CY showed a DMF of , 1-2-1-3 for MISO (0.33 mg/g)
and -0'8 for WR 2721 (400 mg/kg). Neither modifying agent appeared to cause any
consistent change in the pattern of body-weight loss after CY, but WR 2721 reduced
the myelosuppression seen at 3-4 days after CY.
The data suggest that modification of tumour response to CY by the addition of
MISO varies from tumour to tumour, and is very dependent upon the MISO dose.
The protective effect of WR 2721 when combined with CY Is not confined to normal
tissues, and at a dose of400 mg/kg may be as great in terms of tumour response as in
terms of acute LD50 in this system. At a lower dose of WR 2721, however, some
differential protection may occur.
MUCH ATTENTION has been paid by
radiobiologists to the problem of killing
hypoxic, radio-resistant cells in solid
tumours without producing unacceptable
damage to the surrounding normal tissues.
Two quite separate approaches have been
found experimentally successful and are
currently undergoing clinical trial. The
first ofthese is the use ofsubstances which
selectively radiosensitize hypoxic cells
whilst not changing the response of well-
oxygenated cells (e.g. misonidazole, MISO)
(Adams, 1977). The second approach has
been to use sulphydryl radio-protective
agents which are selectively excluded from
tumour tissue (e.g. WR 2721) (Yuhas,
1980a).
Recent studies have shown that these
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two agents can, in addition to their inter-
action with ionizing radiation, also modify
the response to various cytotoxic drugs.
The hypoxic cells in solid tumours may
well represent a population resistant to
chemotherapy because of their distance
from the blood supply, low rate of pro-
liferation or hypoxia per se. MISO has
been shown to be selectively cytotoxic to
hypoxic cells both in vitro and in vivo
(Hall & Roizin-Towle, 1975; Brown, 1977),
and may therefore be effective against
those cells which survive conventional
drug treatment. It has also been demon-
strated that hypoxic pretreatment with
MISO invitro can sensitize cells tonitrogen
mustard, melphalan and cis-platinum
(Stratford et al., 1980). A clear enhance-7P. R. TWENTYMAN
ment of cell kill in the Lewis lung tumour
by the addition of MISO to cyclophospha-
mide (CY) and melphalan has been repor-
ted by Rose et al. (1980), whilst Clement
et al. (1980) have shown a variable en-
hancement of the anti-tumour activity of
alkylating agents by MISO over a range of
mouse tumours.
A series of studies by Yuhas and his
co-workers has shown that WR 2721 is
able to protect mice from the toxic effect
of nitrogen mustard (Yuhas, 1979) and
CY (Yuhas, 1980b), and rats from cis-
platinum-induced kidney damage (Yuhas
& Culo, 1980). In both ofthese studies, the
alteration in tumour response to the
chemotherapy was minimal. Differential
protection by WR 2721 of normal mouse
marrow cells as compared with the
EMT6 tumour, has also been shown for
a number of different cytotoxic drugs
(Wasserman et al., 1981).
In this paper, experiments are described
in which CY treatment has been combined
with either MISO or WR 2721. Growth
delay in two different sarcomas of the
C3H mouse has been used as a measure of
tumour response. Loss of body weight,
change in white-cell count and lethality
have been stuidied as indicators of host
response.
MATERIALS AND METHODS
Mice and tuanours.-The mice used in
these studies wiere inbred C3H/He supplied
by OLAC. Females wNere used in most experi-
ments, but males w-ere used occasionally.
Mice entered experiments at age 12-16
wAeeks and weighed 20-28 g.
Tumours used were the KHT and RIF-1
sarcomas, both of wAhich originated in C3H/
Km mice at Stanford University, California,
and w,hich have been previously described
(Kallman et al., 1967; Twentyman et al.,
1980). The methods used for tumour cell
inoculation into the gastrocnemius muscle of
the hind limb and subsequent measurement
of tumour growNth, including conversion of
leg measurement to tumour weight, have also
been described (Twentyman et al., 1979). The
endpoint ofgrowth delay was calculated from
the time taken for individual tumours to
reach 4 x the initial group-mean treatment
volume. Tumours were treated in the size
ran-ge 300-600 mm3.
Nine to 12 mice were used in each treat-
ment group.
White-cell couants.-Mice wNere lightly
anaesthesized with ether and blood samples
wN-ere taken by cutting a fewA mm from the end
of the tail with a scalpel. A capillary pipette
was then used to draw up 0 02 ml of blood,
which was diluted in 20 inl of 'Isoton"
(Coulter Electronics Ltd). Six drops of
"Zapoglobin" were added to lyse the red
cells, and counts were made on an electronic
particle counter (Coulter Electronics-model
ZB1).
Drugs. Misonidazole (MISO), kindly sup-
plied by Roche Products Ltd, was dissolved
in Hanks' balanced salt solution (HBSS) at a
concentration of 25 mg/ml. WR 2721 (S,2-
(3-aminopropylamino)ethyl - phosphorothioic
acid) was supplied by the Drug Development
Branch, U.S. National Cancer Institute, and
was dissolved in HBSS at a concentration of
20 mg/ml. Both drugs were freshly prepared
immediately before administration and were
given to mice by the i.p. route. Cyclophos-
phamide (CY, WB Pharmaceuticals Ltd) was
also dissolved in HBSS at various concentra-
tions and administered in a volume of 0 005-
0 02 ml/g by the i.p. route. Control mice, or
those being treated with CY alone, wrere given
appropriate additional volumes of HBSS,
equivalent to the volumes in which the
MISO w%as delivered. Except where otherwise
stated, MISO was given at the same time as
CY, and WR 2721 was given 30 min before
CY. In our mice, LD50 values for MISO and
WR 2721 alone are - 1-4 g/kg and 550 mg/kg
respectivelv.
RESULTS
Tiumour response-Effect of MISO
RIF-i. The results from 2 experiments
in which mice bearing the RIF-1 tumour
were given various doses of CY either
with or without MISO (1 mg/g) are shown
in Fig. 1. It will be seen that the principal
effect ofadding the MISO is to remove the
initial shoulder from the curve of growth
delay vs dose of CY alone. For a growth
delay of 5 days, therefore, the dose modi-
fying factor is in excess of 2 0, but it has
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FIG. 1.-Change in growth deli
CY in the RIF-1 tumour.
CY alone. Open circles, CY
1 mg/g MISO. The two par
from separate experiments
represents 9-12 mice. Error I
fallen to 1-3-1-4 for a growth delay of 15
T/ / 4!/ days.
The results from two further experi-
,/l/ ments performed at a lower MISO dose
(033 mg/g) are shown in Table I, and
results from 2 experiments in which the
MISO dose was varied are shown in Table
II. It may be seen that the magnitude of
(a) the effect falls with the MISO dose, and
that the enhancement is not always
significant at a dose of 0-33 mg/g MISO.
The effect of time between administration
150 200 of MISO and CY is shown in Fig. 2. For
maximum tumour response, the MISO
-. may be given at any time up to 2 h before
I,-' '~ CY (including simultaneously) but ad-
'f ' ,/ ministration in the reverse order is much
j less effective. It should.be noted, however,
that these conclusions regarding timing
may not necessarily apply for different A MISO doses, or indeed for different tu-
mours and/or normal tissues. (b) As the dose-modifying effect of the
addition of MISO to CY was greatest at
75 ioo low CY doses, an experiment was carried
thd f out in which 5 daily doses of CY were
Closed circles, given with or without simultaneous MISO.
+simultaneous The results are in Table III. At the lower nels show data dose of CY, there was no significant
s. Each point
bars are +2 s.e. increase in tumour-growth delay nor was
TABLE I.-Response of the RIF-I tumour to CY alone and in combination with MISO
(0-33 mg/g)
MISO CY dose (mg/kg)
(0 33 mg/g) A
Expt simult. 0 33 67 100 200
A - 00 2-8 + 0-8 6-4+1-0 16-3+ 2-0
+ 0-1+0-6 3-4+1-0 12-3+1-3 19-4+1-7
B - 00 3-6+2-0 9 7+3-1 19-5+6-4 22-3+3-7
+ -0-4+ 1-4 3-1+ 1-8 11-9+3-0 17-6i3-9 21-6+2-6
All values are mean growth delay (days) for groups of 9-12 mice.
Error limits show + 2 s.e.
TABLE II.-Response of the RIF-1 tumour to CY alone and in combination with varyiny
doses ofMISO
MISO dose (mg/g)
CY dose , A__
Expt (mg/kg) 0 0 0-33 0-67 1-0
A 100 10-2+1-5 11-2+0-8 13-1+1-7 15-2+1-5
B 75 8-6+0-8 11-6+1-3 14-1+1-5 14-9+2-0
All values are mean growth delay (days) for groups of 9-12 mice.
Error limits sbow + 2 s.e.
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FIG. 2. Growth delay in RIF-l tumour given
CY alone, or with MISO (1 mg/g) with
differing intervals between the 2 drugs.
Two separate experiments are shown.
0, CY 75 mg/kg; *, CY 100 mg/kg. Each
point represents 9-12 mice. Error bars are
+ 2 s.e.
there any increase in toxicity. The higher
dose of CY was enhanced by the addition
of MISO, but the effect is not significant,
because of the small number of animals
surviving repeated administration at this
dose level.
KHT.-The effect of administering
1 mg/g MISO simultaneously with CY to
animals bearing the KHT tumour is shown
in Table IV. In Experiment A, no sig-
nificant increase in growth delay was
brought about by the addition of MISO.
In Experiment B, small but significant
increases were seen. Two experiments in
which lower doses of MISO were used are
shown in Fig. 3. The increase in growth
delay caused by the addition of MISO
is again seen to be similar at all doses of
CY, indicating a loss of initial shoulder
rather than change in the subsequent
slope ofthe curve.
A multiple-dose experiment similar to
that for the RIF-1 tumour was also done
for KHT. The results are shown in Table
V. Growth delays of 3-3 and 15'1 days
for CY alone were increased to 8-9 days
and 23-0 days respectively with the addi-
tion of MISO. If the growth delay vs
dose curve is linear in this region, these
TABLE III.-Response of C3H mice and ofthe RIF-1 tumour to 5 daily doses of CY alone
or in combination with MISO
Tumour-
growth Weighli
MISO CY delay* change
(0-33 g/kg/d) (mg/kg/d) (days) (%O)
- 0 0-0 +1-1+1-
+ 0 0-4+1-6 +0-9+1-
- 20 8-7+3-5 -4-9+2
- 40 17-9+4-5 -8-7+3
+ 20 97+3-0 -19+1
+ 40 25-7+8-0 -13-8+2-
* Means for 10 mice.
t Between Day 0 and Day 7 after first treatment.
Error limits show + 2 s.e.
;
i.
II
6
4
8
Survivors
on I)ay 30
10/10
10/10
9/10
5/10
10/10
3/10
TABLE IV.-Response of the KHT tumour to CY alone or in combination with MISO
(1 mg/g)
CY dose (mg/kg)
MISO
Expt (1 mg/g) 0 37-5 50 75 100
A - 00 7-3+0-6 13-8+0-9
+ 0 4+ 0-25 7-5+ 03 14-9 +0-8
B - 00 7-1+0-3 15-0+1-5
+ 0 3+ 0-6 9-1 + 1-5 19-7 + 2-2
All values are mean growtlh delay ((lays) for groups of 9-12 mice ± 2 s.e.
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TABLE VI.-Response ofthe RIF-1 tumour
to CY alone or in combination with
WR 2721
/
A /
33 67 100
CY WR 27,
Expt (mg/kg) (mg/kg
A 75
75 200 at -34
75 400 at -34
75 400 at -64
B - 400 at -34
100
100 400 at -3(
C 250/d x
20/d x 5
150 20/dx 5 250/dx
'21
g)
04 min
0 min
04 min
04 min
0 min
<5
5
CY (mg/kg)
FIG. 3.-Change in growth delay with dose of
CY in the KHT tumour. 0 or *, CY alone;
0, CY+simultaneous 0 33 mg/g MISO;
A, CY+simultaneous 0-6 mg/g MISO.
Points are mean growth delay for groups of
9-12 mice. Error bars are + 2 s.e.
TABLE V.-Response of the KHT tumour
to CY alone or in combination with MISO
and/or WR 2721,
doses
M
(0-3
g/l
[ISO WR 2721
in a schedule of 5 daily
3 mg/ (250mg/ CY
rday) kg/day) (mg/kg/day)
0
+ - 0
+ 0
- - 20
- - 40
+ - 20
+ - 40
+ 20
- + 40
+ + 40
* Means for 9-12 mice + 2 s.e.
Tumour-
growth*
delay
(days)
0.0
-0-2+0-5
0-8+ 1.0
3-3+2-2
15.1+1-2
8-9+ 1-0
23-0 + 2-2
1-6+1-4
10-0+ 1-6
15-7+ 1-6
data indicate a dose modifying factor
(DMF)* ofaround 1-5.
Tumour response-Effect of WR 2721
RIF-1.-The results of 3 experiments
in which WR 2721 was administered to-
gether with CY to animals bearing the
RIF-1 tumour, are shown in Table VI. In
* Mean of 9-12 mice + 2 s.e.
each case the growth delay was less than
that due to CY alone. An experiment
in which complete CY dose-response cur-
ves were obtained is shown in Fig. 4. It
will be seen that the slopes of the curves
are similar, and that a reduction in growth
delay of around 2 days is produced by
adding WR 2721 (400 mg/kg) to any of
the CY doses. The DMF therefore changes
from 0 5 at a CY dose of 50 mg/kg, to
0 8 at 150 mg/kg.
15
( 5 ,-///1/~~
0 50 100
CY (mg/kg)
150 200
FIG. 4. Change in the growth delay with
dose of CY in the RIF-1 tumour. 0, CY
alone; 0, CY+WR 2721 (400 mg/kg) 30
min earlier. Each point represents 9-12
mice. Error bars are + 2 s.e.
* In this paper, dose-modifying factor (DMF =
Dose of CY to produce a given effect
Dose of CY in presence of modifying agent to give same effect
DMF > 1-0 therefore indicates sensitization, and DMF < 1-0 indicates protection.
20
16
12
cx
a
0
(3
81
41
0l
Growth
delay*
(days)
8-6+ 1-5
7-3 +1-3
6-0+ 1-4
4*7+1.1
0*4+0-8
16-3 + 3-8
9-1+2-7
1-7+2-1
8-7+3-5
6-8+2*1
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TABLE VII.-Response of the KHT tumour to CY alone or in combination with WR 2721
CY WR 2721 WR 2721 WR 2721
WR 2721 WR 2721 (75 mg/kg) 4 60 min 4 30 min +CY
(mg/kg) alone alone CY CY together
200 11-3+0 4 9-9+0*7 10*1+0*9 10-6+0-8
400 0-8+0-4 11-3+0-4 8 5+1-4 7-7+0-5 8 8+0 7
All values are mean growth delay for 9-12 mice + s.e.
KHT.-The effect of combining WR
2721 with CY in the KHT tumour is
shown in Table VII. The reduction in
growth delay due to the lower dose of
WR 2721 is of marginal significance in
each case. At the higher dose, however,
a highly significant reduction of 3-4 days
is seen from the value of 12 days obtained
by adding the delays due to CY and
WR 2721 alone. There does not appear to
be any great dependence of this effect on
the relative times of administration of the
two agents. On the basis of the previously
determined shape of the CY response
curve for this tumour (e.g. Fig. 3) the
DMF for 400 mg/kg WR 2721 thus lies in
the region of 0-8.
The results of combining WR 2721 with
CY during repeated daily administration
are shown in Table V. Once again, there is
a significant reduction from the effect of
CY alone. If it is assumed that the dose-
response curve for CY alone in the region
of20-40 mg/kg/day is linear, the reduction
from 15-1 to 10-0 days indicates a DMF
of 0 7. Also in this experiment, we
included a group which received both
MISO and WR 2721 in combination with
CY. It may be seen that the net effect
is about the same as that due to CY alone;
TABLE VIII.-Modification of CY LD50 by MISO or by WR 2721
Expt
A
Treatment
CY alone
CY+MISO (0-33 mg/g)
B CY alone
CY+MISO (0 33 mg/g)
CY+WR 2721 (400 mg/kg)
C CY alone
CY+MISO (0-33 mg/g)
CY+WR 2721 (400 mg/kg)
D CY alone
CY+WR 2721 (400 mg/kg)
E CY alone
CY+WR 2721 (200 mg/kg)
F CY alone (5 x daily dose)
CY+WR 2721 (250 mg/kg/day)
LD50 (95% C.L.)
(mg/kg)
284 (251-317)
j 240
217 (190-244)
137 (96-179)
313 (251-375)
273 (215-331)
4z 240
334 (303-365)
225 (200-250)
232 (193-272)
252 (218-285)
374 (343-405)
45-1 (
54.9 (49.9-59.9)
DMF
:> 1-18
CONT=
MISO
= 1-58
CONT _=06
WR 2721
CONT 1-14
CONT -0-82
WR 2721
0 97
0-67
0-82
All LD50 values determined at 30 days after treatment except: Expt A at 24 days; Expt C at 100 days.
LD50 values and 95% confidence limits computed using the GLIM programme for probit analysis.
DMF (dose modifying factor)-=D5 LD50 (CY alone)
LD5 (CY+modifying agent)
In the two cases where the LD50 value isgiven as 1- 240, the survival did not fall below 5000 at the highest
dose administered.
* The survival fell from 100% to 0% at adjacent drug doses, hence not allowing reliable estimation of
confidence limits.
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i.e. the 2 modifying agents cancel each
other out.
Hosteffects
Lethality.-In early experiments, it was
found that the combination of MISO
(1 mg/g) with CY produced very variable
lethality, with deaths occurring at CY
doses as low as 50 mg/kg. These deaths
usually happened within 48-72 h of drug
administration, and were therefore
ascribed to CY enhancement of MISO
toxicity, rather than the reverse. The main
toxicity experiments were therefore car-
ried out using 0 33 mg/g of MISO.
The results of several experiments in
which modification of CY lethality by
either MISO or WR 2721 was studied are
shown in Table VIII. In two of the
experiments (A and C) the survival fell to
50% at the highest CY dose given with
MISO. The LD50,, are therefore given as
a lower limit (i.e. -4C the maximum dose
used) but are likely to be close to these
values. For MISO (0.33 mg/g) given simul-
taneously with CY, DMF values are
1 18, 1 58 and 1*14. For WR 2721 given
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FIG. 5.-Percentage change in body weight at
Day 6 or 7 after CY. Closed symbols, CY
alone. Open symbols, CY+simultaneous
MISO. *, 0 + MISO (1 mg/g) to mice with
RIF-1 tumour; A,A ±MISO (0-33 mg/g)
to mice with KHT tumour; y, V±MISO
(0-33 mg/g) to non-tumour-bearing mice;
*, + MISO (0 33 mg/g) to non-tumour-
bearing mice. 5-12 mice/group. Percentage
weight change calculated from group means
at Days 0 and 6/7.
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FIG. 6. Percentage change in body weight at
Day 6 or 7 after CY. Closed symbols, CY
alone. Open symbols, CY+WR 2721 at
-30 min. *,O±WR 2721 (200mg/kg) to
mice bearing RIF-1 tumour; , A +WR
2721 (400 mg/kg) to non-tumour-bearing
mice; E, ± WR 2721 (400 mg/kg) to mice
bearing RIF-1 tumour; V, V±WR 2721
(400 mg/kg) to non-tumour-bearing mice;
*, +WR 2721 (400 mg/kg) to non-
tumour-bearing mice. 5-12 mice/group.
Percentage weight change calculated from
mean weight at Days 0 and 6/7.
30 min before CY, DMF values are 0-67
(WR 2721=200 mg/kg) and 0-69, 0-82
and 0-97 (WR 2721=400 mg/kg). In
the experiments where 5 daily doses of
CY were combined with WR 2721 (250
mg/kg) DMF was 0-82.
Weight loss.-The results of a number
of experiments in which loss of body
weight after CY treatment was studied,
are shown in Figs 5 and 6. In Fig. 5, data
for CY alone are compared with data
for CY +MISO, and in Fig. 6, data for CY
alone are compared with data for CY+
WR 2721. The doses of the modifying
agents varied from experiment to experi-
ment, and are shown in the figure legends,
as is the information as to whether or not
the mice were tumour bearing. Weight
loss was determined 6 or 7 days after CY
administration, which was generally
found to be the nadir.
The data show that, although in general
the weight loss increases with dose of CY,
the inter-experimental variation is very
large. Close examination of the points
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from any particular experiment fails to
show any consistent tendency for either
MISO or WR 2721 to modify the weight
loss response.
White-cell count. It was found in pre-
liminary experiments that, after various
doses of CY, the nadir in white-cell count
was on the 3rd or 4th day, with a rapid
recovery thereafter, leading to an over-
shoot by Day 7. Experiments were there-
fore carried out to examine the effect of
adding either MISO or WR 2721 to CY
upon the white-cell count at Days 3 or 4.
The results of 2 separate experiments are
shown in Fig. 7. In both of these experi-
ments, as in several others similar, the
white-cell count in control mice rose
between Day 0 and Day 3/4, presumably
as a result of the sampling procedure.
The results are therefore expressed as
15)
S
'U 10)
50
X o
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m
0 33 67 100
CY (mg/kg)
50 ,
(b)
A------
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11
> 9
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50 11-~~~~~~~~~~~~~~
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- 5 ;
CY (mg/kg)
Foce. 7.-Change in white-cell count in tail-
vein bloocl with (lose of CY. 0, CY alone;
A, CY +simultaneous MISO (1 mg/g);
*, CY+WR 2721 (400 mg/kg at -30
min). The panels show 2 separate experi-
ments. For each treatment group (including
controls) thle results are expressed as count
on Day 4 (a) or Day 3 (b) as a % of Day 0.
This allows changes in the white-cell count
in control animals to be shown. Means for
5 or 6 mice. Error bars show + 2 s.e.
count on Day 3 or 4 as a %0 of count on
Day 0 for each treatment group. The
curves for CY alone and for CY+MISO
(1 mg/g) are similar for both experiments.
For CY alone, a progressive fall in the
Day 3 or 4/Day 0 ratio is seen with
increasing CY dose. With MISO pre-
treatment, the initial rise above 100%
is not seen, but apart from this, there is no
apparent steepening of the curve with
increasing CY dose.
For WR 2721 pretreatment, the results
shown in Fig. 7, panel (a) are difficult to
interpret, because of the almost doubling
of the count between Days 0 and 4 for
mice receiving WR 2721 alone. There
certainly appears to be no protection at
33 mg/kg ofCY, but there is an apparently
significant protection at the higher doses.
All or part ofthis, however, may be related
to the effect of WR 2721 alone in raising
the Day 4 count. In the second experi-
ment, where there was no count elevation
by WR 2721, there is only a significant
protection at 67 mg/kg of CY. Taken to-
gether, these 2 experiments, together with
an additional experiment (not shown),
indicate a tendency for WR 2721 to pro-
tect against CY depression of the white-
cell count. It is not possible, however, to
calculate a DMF for the effect, because of
the complex shape of the curves.
DISCUSSION
Whereas MISO at a dose of 1 mg/g
clearly increases the growth delay due to
CY in the RIF-1 tumour, this is not true
in KHT (though it should be noted that
enhancement is seen in KHT using lower,
fractionated doses). This is the opposite
of what would, perhaps, have been expec-
ted if enhancement depended on the pre-
sence within the tumour of a considerable
proportion of radiobiologically hypoxic
cells. The RIF-1 tumour growing intra-
muscularly has essentially no cells which
are fully hypoxic, and when growing in
the flank has a hypoxic fraction of only
2% (Brown et al., 1980) whereas KHT in
the flank has a hypoxic fraction of 14%
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(van Putten & Kallman, 1968). (There
are no data available for KHT growing
intra-muscularly.)
The shape of the curve for MISO + CY
in RIF-1 (Fig. 1) also argues against the
effect being due to sensitization of a rela-
tively CY-resistant fraction of cells, be-
cause the major enhancement occurs at
low CY doses. Such an effect would rather
reflect either a specific sensitization of a
relatively CY-sensitive subpopulation, or
a lethal interaction between sub-lethal
damage caused by the two individual
agents.
In both tumour systems, there is only
a small enhancement of CY response by
0 33 mg/g of MISO, and, in terms of
blood levels which can be achieved in the
clinic, this is still a very high dose. (The
longer half-life of MISO in man may,
however, contribute to enhancement des-
pite lower peak levels.) In a study very
similar to that reported here, Law et al.
(submitted) have also found an enhance-
ment of CY growth delay in the RIF-1
tumour by 0 75 mg/g of MISO. They also,
however, found that a dose enhancement
of about 2 in the early part of the curves
gave way to parallel curves above a CY
dose of about 50 mg/kg. In Tannock's
(1980) study, it is not possible to calculate
dose-modifying factors because of the
limited number of CY doses, but clear
enhancement of CY growth delay is seen
by MISO (1 mg/g) in both the KHT
sarcoma and the 16/C carcinoma. Again
using growth delay as an endpoint,
Clement et al. (1980) have shown enhance-
ment of CY response by MISO (0-6 and
1P0 mg/g) in the M5076 and Lewis lung
tumours, but no enhancement was found
in the B16 melanoma.
In the originally reported work of Rose
et al. (1980) a CY dose-modifying factor of
2 was found for MISO (1 mg/g) in the
Lewis lung tumour. It seems clear that
although enhancement of CY response has
been seen by very high doses of MISO, it
is not universal in all tumours, and the
effect may be rapidly lost with a reduction
in MISO dose. The question whether such
enhancement represents an improvement
in therapeutic index is even more open.
Rose et al. (1980) did not present normal
tissue data for CY, but for another alkylat-
ing agent (melphalan) they showed that
the dose enhancement seen against mar-
row stem cells was less than that for the
Lewis lung tumour. Tannock (1980) on
the other hand, using weight loss and
depression ofwhite-cell count as endpoints
of normal tissue toxicity, concluded that
addition of MISO to CY was therapeutic-
ally disadvantageous in his studies. The
combination appeared to be advantageous
for treatment of the M5076 ovarian car-
cinoma, but disadvantageous in the B16
melanoma (Clement et al., 1980).
In their studies comparing RIF-1 tu-
mour response with marrow stem-cell
response, Law et al. (submitted) show an
improved therapeutic index for CY doses
below 100 mg/kg, but above this dose the
picture is less certain. Our studies reported
here seem to support the less encouraging
view of the likely usefulness of the com-
bination. It is true that MISO (1 mg/g)
does not appear to systematically increase
CY-induced weight loss, nor does it greatly
increase depression of white-cell count by
CY. There may well, therefore, be a thera-
peutic gain at low (and clinically relevant)
doses of CY in the RIF-1 tumour, where
the dose enhancement is 2. In the KHT
tumour, however, the enhancement at
1 mg/g ofMISO is much less than in RIF-1,
and at a MISO dose of 0 33 mg/g the
enhancement in RIF-1 is considerably
reduced. This reduced MISO dose does,
however, cause a small but repeatable
decrease in the LD50 of CY, and may not,
therefore, betherapeuticallyadvantageous.
At the moment, there is no clear
indication of the mechanism whereby
MISO enhances tumour response to CY.
As mentioned earlier in this discussion,
several aspects of the data would argue
against it being directly related to en-
hanced killing of hypoxic cells. One thing
that is clearly established is that high
doses of MISO cause a severe and pro-
longed reduction in body temperature in
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mice (G-omer & Johnson, 1979). It would
appear likely that this could cause pro-
found alterations in CY metabolism,
which would involve enzyme action.
However, it is difficult to see how this
could result in improvement in therapeutic
ratio, as has been reported in some of the
studies detailed above. Furthermore, it
has been shown that enhancement of
tumour response to CY can be caused by
another radiosensitizer (SR 2508) which
does not cause a drop in body temperature
(Law et al., submitted). There is evidence
also that MISO may inhibit the recovery
from CY-induced potentially lethal dam-
age in the RIF-1 tumour (Law et al.,
submitted) but this may itself be related
to possible pharmacokinetic alterations.
Our studies with WR 2721 show that
the relative protection of normal tissue
compared with tumour response in our
system is less than might have been
expected from other data in the literature.
Although 200 mg/kg has only a small effect
on the CY response of either tumour, the
higher dose of 400 mg/kg produces a
IDMF for tumour response of 0 5-0-8,
depending upon CY dose. This compares
with a mean value of 0-8 for lethality. In
his studies on nitrogen-mustard lethality,
Yuhas (1979) found a DMF of 0 5 for
350 mg/kg of WR 2721, and, in rats,
Yuhas & Culo (1980) found a DMF of
- 0'6 for kidney damage if WR 2721
(200 mg/kg) were given before cis-
platinum. More recently, Yuhas (1980b)
reported a DMF of 0 7 for CY lethality
in mice pretreated with 200 mg/kg of WR
2721. Using marrow CFUs as an endpoint,
Wasserman et al. (1981) found a DMF of
- 0-4 for WR 2721 (600 mg/kg) injected
before CY. In this latter study, the growth
delay in the EMT6 tumour due to CY was
reduced from 12 to 10 days by pretreat-
ment with WR 2721, whereas in the other
3 studies (Yuhas, 1979; Yuhas, 1980b;
Yuhas & Culo, 1980) no change in tumour
response was seen when WR 2721 was
injected 30 min or more before the cyto-
toxic drug.
The question ofthe relationship between
dose modification and the injected dose of
WR 2721 is important. For whole-body
radiation, Yuhas (1980a) studied the pro-
tection against bone marrow death in 4
strains of mice. He found a DMF around
0 5 at 200 mg/kg and 04 at 400 mg/kg;
i.e. most of the protection occurred at
low doses of WR 2721. In the work with
nitrogen mustard, however, Yuhas (1979)
found DMFs of 0-65, 0 50 and 0-65 at
200, 400 and 500 mg/kg of WR 2721
respectively. The reduced protection at the
highest dose was ascribed to an artefact
of a direct toxic interaction between the
two agents, rather than a failure of pro-
tection per se. One reason given for this
was that deaths in this group occurred
much earlier than those in groups receiving
HN2 alone, or HN2 plus low doses of WR
2721. In our studies, however, no such
unusually early deaths were seen, and
hence it appears unlikely that we are seeing
a similar toxic interaction when combining
400 mg/kg ofWR 2721 with CY. The DMF
for lethality in the one experiment with
200 mg/kg of WR 2721 was, however,
similar to that at 400 mg/kg, though the
tumour protection is much less at this dose
(Table VII). This would suggest that
optimal relative protection may be seen
for reduced WR 2721 dose.
Our results suggest that the differential
protection against CY produced by WR
2721 may be considerably less than that
reported for radiation (Yuhas, 1980a) or
for nitrogen mustard (Yuhas, 1979). A
differential protection may be seen at
relatively low doses of WVR 2721 but this
is lost with increasing dose.
I wN-islh to thlank Daryl Knighit for lhei excellent
teclhnical assistance ai(I Jill SlhawF for caring for the
animals use(l in these studies.
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